Amarin shares surged in Monday’s premarket after the biopharmaceutical company’s fish oil capsule showed dramatic benefits to heart patients in a clinical trial.
Amarin said its capsule, Vascepa, significantly reduced serious cardiovascular events over a placebo in trial results involving 8,179 statin-treated adults with elevated cardiovascular risk.
“We are delighted with these topline study results,” John Thero, president and CEO of Amarin, said in a press release. The company said the trial met the primary endpoint with a 25 percent risk reduction.
